Radiotherapy for metastatic prostate cancer

Affiliations

¹ Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA. Electronic address: aaparicio@mdanderson.org.
² Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.

Comment

Ana Aparicio et al. Lancet. 2019.

. 2019 Sep 7;394(10201):829-830.

doi: 10.1016/S0140-6736(19)31783-0.

¹ Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA. Electronic address: aaparicio@mdanderson.org.
² Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA.

No abstract available

Comment in

Radiotherapy for metastatic prostate cancer-Authors' reply.
Parker CC, James ND, Brawley CD, Clarke NW, Parmar MKB. Parker CC, et al. Lancet. 2019 Sep 7;394(10201):830. doi: 10.1016/S0140-6736(19)31829-X. Lancet. 2019. PMID: 31498099 No abstract available.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Parker CC, et al. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21. Lancet. 2018. PMID: 30355464 Free PMC article. Clinical Trial.